A global study led by Paresh Dandona, MD, PhD, found a majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels.
Twelve faculty members with varied research and clinical expertise have joined the Jacobs School of Medicine and Biomedical Sciences over the past several months.
Researchers in the Division of Endocrinology, Diabetes and Metabolism have found that dapagliflozin, designed for Type 2 diabetes, can benefit patients with Type 1 diabetes.
A record number of residents, fellows, junior faculty and medical students presented their research results in areas including new treatments for endocarditis, overcoming cardiovascular health disparities and boosting mitochondrial health during the Department of Medicine’s fourth annual Research Day.
A study led by Paresh Dandona, MD, PhD, and published online in Diabetes Care shows overweight and obese Type 1 diabetics saw the most significant improvements — including a reduction in blood sugar — in a randomized clinical trial of liraglutide.